Centro de Investigación del Cáncer

What Centro de Investigación del Cáncer does

Centro de Investigación del Cáncer (CIC-IBMCC) is a Spanish non-profit cancer research institute jointly operated by the University of Salamanca (USAL) and the Spanish National Research Council (CSIC), managed through the Fundación de Investigación del Cáncer de la Universidad de Salamanca (FICUS). Founded in 1998 and headquartered on the USAL campus in Salamanca, the center employs 242 scientists across 16 research groups organized into two programs: Molecular Mechanisms of Cancer and Translational and Clinical Research in Cancer. Its service portfolio spans five ISO-certified core facilities (Advanced Cellular Analyses, Genomics, Mouse Model Experimentation, Pathology, Proteomics) and four diagnostic services (Cancer Genetic Counseling, Cellular Diagnostics, Cytogenetic Diagnostics, Molecular Biology), the latter serving over 100 Spanish hospitals including reference work for Castilla y León regional hospitals and national hematology cooperative groups (PETHEMA, GEL-TAMO, GEM, GETH). The center also runs a Master's program ranked 2nd in Spain in Biosciences (El Mundo 2025–2026), a PhD program, the 11-university Coimbra Life Sciences Group Master in Cancer Biology, and a Mentoring Program under its HRS4R-aligned HR strategy.

CIC's core technology is a multi-disciplinary cancer research platform combining basic molecular biology, translational oncology, and clinical research, underpinned by advanced infrastructure including STED/PALM-STORM nanoscopy, BD-FACS-Aria III multiparametric cell sorting, nano HPLC-MS/MS proteomics, NGS and microarray genomics, DISCOVERY ULTRA pathology, and in vivo mouse modeling. Revenue is generated through three streams: institutional and competitive research funding (CSIC, USAL, FICUS, ISCIII, MINCINN, ERC, FEDER, Junta de Castilla y León, AECC, Cancer Research UK, pharma); service fees from core facilities and diagnostic services charged to external researchers, hospitals, and public/private institutions via published rate sheets; and tiered donations (Platinum >€10,000, Gold €5,000–10,000, Silver €2,000–5,000, Honor €1,000) processed through FICUS under Spain's Law 49/2002 non-profit regime. The Innovation Office additionally supports technology transfer to pharma/biotech and has spawned four biotech spin-offs (300k.bio, Egogenomics, Cytognos, Immunostep).

Name

Centro de Investigación del Cáncer

Legal name

Centro de Investigación del Cáncer (CIC-IBMCC)

Website

https://cicancer.org

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Centro de Investigación del Cáncer (CIC-IBMCC) is a joint USAL-CSIC non-profit cancer research institute in Salamanca, Spain, operating 5 core facilities and 4 diagnostic services serving 100+ hospitals, with training programs and 242 scientists across two research programs.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Colleges, Universities, and Professional Schools (6113), Other Scientific and Technical Consulting Services (54169), Professional, Scientific, and Technical Services (54)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700), Services-Educational Services (8200)

akta.pro primary industry

Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

akta.pro secondary industry

Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Cancer research services
• Biomedical research institute
• Genomic diagnostics
• Proteomics services
• Postgraduate training programs

Headquarters

HQ city

Salamanca

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Institutional and Competitive Research Funding: CIC operates primarily through institutional funding from CSIC, University of Salamanca (USAL), and its foundation FICUS, as well as competitive grants from national and European funding bodies including MINCINN, ISCIII, European Research Council, and regional government.
2. Service Fees from Core Facilities and Diagnostic Services: CIC generates revenue through fees charged for use of core facilities and diagnostic services by internal groups, external researchers, hospitals, and public/private institutions. Published rate sheets exist for services such as genomics, pathology, proteomics, and mouse model experimentation.
3. Donations and Philanthropy: CIC accepts donations through its foundation FICUS, which operates under Spanish Law 49/2002 tax regime for non-profit organizations, offering tax incentives to donors. Donation tiers include Platinum (>10,000 EUR), Gold (5,000-10,000 EUR), Silver (2,000-5,000 EUR), and Honor (1,000 EUR).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

The Centro de Investigación del Cáncer (CIC-IBMCC) is a joint cancer research institute of the University of Salamanca (USAL) and CSIC that delivers basic, translational, and clinical cancer research through two integrated research programs. It operates advanced core facilities (genomics, proteomics, microscopy, pathology, mouse models) and diagnostic services (cytogenetics, molecular biology, cellular diagnostics, cancer genetic counseling) for hospitals and external researchers across Spain. It also runs ranked postgraduate training programs (Master in Biology and Clinic of Cancer; PhD Program) and a mentoring/career development program.

Product overview

The Centro de Investigación del Cáncer (CIC-IBMCC) is a comprehensive cancer research center operated jointly by the University of Salamanca (USAL) and the Spanish National Research Council (CSIC), managed through the Foundation for Cancer Research (FICUS). The center offers an integrated portfolio consisting of: (1) Core Research Facilities providing advanced services in Advanced Cellular Analyses, Genomics, Mouse Model Experimentation, Pathology, and Proteomics; (2) Diagnostic Services including Cancer Genetic Counseling, Cellular Diagnostics (cytometry), Cytogenetic Diagnostics, and Molecular Biology Services; (3) Academic Programs including a Master in Biology and Clinic of Cancer (ranked 2nd in Spain) and a PhD Program; and (4) Two main Research Programs focused on Molecular Mechanisms of Cancer and Translational and Clinical Research. All core facilities and diagnostic services are supported by ISO certifications (ISO 9001, ISO 45001).

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Cellular Analyses Unit Microscopy and cytometry services including widefield, confocal laser scanning, nanoscopy with STED, FLIM, TIRFM, PALM/STORM techniques, and BD-FACS-Aria III cell sorting for multicolored fluorescence imaging and multiparametric cell analysis. Targeted at cancer researchers from public and private institutions.
• Genomics Unit DNA sequencing (ABI-3130xl), Affymetrix Gene Chip expression profiling, copy number variation analysis using CytoScan 750K/HD and OncoScan CNV assays, Agilent Bioanalyzer quality control, and home-made microarray printing. ISO 9001 certified. Targeted at cancer researchers and clinicians.
• Mouse Model Experimentation Unit (UEMM) Mouse breeding, genotyping by PCR, DNA extraction, and experimental procedures including IP/SC/IV injections, oral gavage, venipuncture, and animal euthanasia. ISO 9001:2015 certified. Targeted at researchers conducting in vivo cancer studies.
• Pathology Unit Histological, histochemical, and immunohistochemical analysis using DISCOVERY ULTRA (ROCHE) equipment, including in situ hybridization, multiplex, RNA scope, TUNEL, RT-PCR, and FISH for molecular diagnosis. Coordinates the BEOCyL Biobanks Network. ISO 9001:2015 and ISO 45001:2018 certified. Processes approximately 5,640 samples annually from ~504 requests.
• Proteomics Unit Proteome analysis using nano HPLC coupled to mass spectrometry for protein identification, label-free quantification, SILAC-based differential proteomics, and bioinformatics analysis using PEAKS, MAXQUANT, MSFRAGGER, DIANN, and SKYLINE platforms. ISO 9001 certified.
• Cancer and Genetic Counseling Service Hereditary cancer genetic counseling including evaluation of personal and family cancer records, risk assessment, genetic testing, and family research coordination for breast, ovarian, and colorectal cancer syndromes. Targeted at cancer patients, families, and individuals at high hereditary risk.
• Cellular Diagnostics Service (Cytometry) Flow cytometry and cell sorting services for immunophenotyping, cell cycle analysis, apoptosis detection, drug resistance screening, and minimal residual disease detection. ISO-9001:2000 certified. Targeted at hospitals and clinical trial groups.
• Cytogenetic Diagnostic Service Molecular cytogenetic analysis including karyotyping, fluorescence in situ hybridization (FISH), comparative genomic hybridization, genomic microarrays, and next generation sequencing for cancer patients. Serves over 100 hospitals in Spain. Collaborates with Pethema, GEL-TAMO, GEM, GETH on hematological malignancies.
• Molecular Biology Service Molecular analysis of hematological malignancies including B/T-cell clonality testing, chromosomal translocation screening, somatic mutation analysis, gene expression studies, NGS, HLA typing, and hematopoietic chimerism analysis. Reference centre for Castilla y León hospitals; more than 50 hospitals in Spain use the service. Processed 15,978 samples in 2017.
• Master in Biology and Clinic of Cancer Postgraduate Master program providing holistic training in cancer at basic and clinical levels, with hands-on practicum in CIC-IBMCC research labs. 30 places per year, offered under the University of Salamanca academic system. Targets graduates in biology, biotechnology, biochemistry, biomedicine, pharmacology, medicine, and related disciplines.
• PhD Program in Cancer Research

Quantifiable outcome

• 25 years of continuous cancer research with 957 publications in the last decade
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core, minor and major.

• CSIC (Spanish National Research Council)coreStrategic or Co-development PartnerCSIC is one of the two main institutional partners of CIC (CIC-IBMCC), providing research personnel, funding, and institutional support. The IBMCC (Institute of Molecular and Cellular Biology of Cancer) is a joint USAL-CSIC institute. CSIC manages the IBMCC budget, personnel, and accounting alongside FICUS.
• University of Salamanca (USAL)coreStrategic or Co-development PartnerUSAL is the other main institutional partner of CIC. The center is physically located on the USAL campus. USAL provides academic oversight for the Master and PhD programs. The IBMCC is jointly managed by USAL and CSIC.
• FICUS (Fundación de Investigación del Cáncer de la Universidad de Salamanca)coreStrategic or Co-development PartnerFICUS is the foundation managing cancer research at CIC. It handles donations, human resources policy for its employed staff, accounting, budgeting, and fiscal obligations. FICUS received HR Excellence in Research award in September 2019 and manages the HRS4R action plan. It operates under Spanish Law 49/2002 for non-profit organizations.
• CIBER-ONC (CIBER for Oncology)coreStrategic or Co-development PartnerCIBER-ONC is a national biomedical research network focused on cancer. CIC participates in this collaborative network as a research center contributing to and benefiting from coordinated cancer research efforts.
• Conexión-Cancer CSICcoreStrategic or Co-development PartnerCSIC's cancer research connection network that coordinates cancer research across multiple CSIC institutes, providing collaborative framework for CIC's research activities.
• TERAV (Red Temática de Investigación en Avanzada en Valencia)minorStrategic or Co-development PartnerThematic research network providing collaborative framework for advanced cancer research involving CIC.
• NUCLEUS Platform - University of SalamancaminorStrategic or Co-development PartnerUniversity of Salamanca's technology platform providing additional specialized services to CIC researchers including Animal Facility, Bioinformatics, Cell Analysis, DNA Bank, DNA Sequencing, Electron Microscopy, NMR, Elemental Analysis, Transgenesis, X-Ray Diffraction, and In Vivo Imaging.
• IBSAL (Instituto Biosanitario de Salamanca)majorStrategic or Co-development PartnerSalamanca Biomedical Research Institute that coordinates biomedical research in the region, with CIC researchers collaborating on projects and the CIC Proteomics Platform serving as a reference.
• PETHEMA, GEL-TAMO, GEM, GETH (Spanish Hematology Research Groups)majorStrategic or Co-development PartnerSpanish cooperative research groups in hematological malignancies that collaborate with CIC's Molecular Cytogenetic Service and Molecular Biology Service for genetic characterization of patients in clinical trials.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Institut Curie:
• Deutsches Krebsforschungszentrum (DKFZ): Germany's largest biomedical research institute and one of the world's leading cancer research centers. DKFZ operates on a far larger scale than CIC but shares the model of integrated basic-to-translational research, core facilities, and graduate training programs.
• Francis Crick Institute: UK's flagship biomedical research institute with a strong focus on cancer biology alongside other diseases. Operates a similar public-research model with advanced core facilities, training programs, and translational research, competing for European talent and grants.

Direct peers

• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's premier public cancer research center, also focused on basic, translational, and clinical oncology research with core facilities and training programs. CNIO is CIC's closest domestic peer and competes for the same national funding, talent, and hospital partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CICancer_com
• Facebookfacebook.com/cicancer
• LinkedInlinkedin.com/company/centro-de-investigaci-n-del-c-ncer-ibmcc-ficus-

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centro de Investigación del Cáncer